NovaBay Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market. The Company�s Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a spectrum of activity against bacteria, viruses and fungi. The Company is focused in three therapeutic markets, which includes Dermatology, Ophthalmology and Urology. The Company is also developing another class of molecule, NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care.